Pharvaris Statistics
Total Valuation
Pharvaris has a market cap or net worth of $2.34 billion. The enterprise value is $2.06 billion.
| Market Cap | 2.34B |
| Enterprise Value | 2.06B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharvaris has 69.88 million shares outstanding. The number of shares has increased by 14.13% in one year.
| Current Share Class | 69.88M |
| Shares Outstanding | 69.88M |
| Shares Change (YoY) | +14.13% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 54.66% |
| Float | 43.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 1,584.10 |
| PB Ratio | 8.06 |
| P/TBV Ratio | 8.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.24, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.24 |
| Quick Ratio | 10.99 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -994.49 |
Financial Efficiency
Return on equity (ROE) is -73.02% and return on invested capital (ROIC) is -46.40%.
| Return on Equity (ROE) | -73.02% |
| Return on Assets (ROA) | -42.31% |
| Return on Invested Capital (ROIC) | -46.40% |
| Return on Capital Employed (ROCE) | -72.58% |
| Weighted Average Cost of Capital (WACC) | -8.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 134 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pharvaris has paid $2.26 million in taxes.
| Income Tax | 2.26M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.33% in the last 52 weeks. The beta is -2.34, so Pharvaris's price volatility has been lower than the market average.
| Beta (5Y) | -2.34 |
| 52-Week Price Change | +44.33% |
| 50-Day Moving Average | 32.10 |
| 200-Day Moving Average | 27.48 |
| Relative Strength Index (RSI) | 49.70 |
| Average Volume (20 Days) | 572,725 |
Short Selling Information
The latest short interest is 985,973, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 985,973 |
| Short Previous Month | 1.12M |
| Short % of Shares Out | 1.41% |
| Short % of Float | 2.29% |
| Short Ratio (days to cover) | 2.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -198.21M |
| Pretax Income | -192.09M |
| Net Income | -194.35M |
| EBITDA | -198.06M |
| EBIT | -198.21M |
| Earnings Per Share (EPS) | -$3.14 |
Balance Sheet
The company has $284.74 million in cash and $851,944 in debt, with a net cash position of $283.89 million or $4.06 per share.
| Cash & Cash Equivalents | 284.74M |
| Total Debt | 851,944 |
| Net Cash | 283.89M |
| Net Cash Per Share | $4.06 |
| Equity (Book Value) | 272.49M |
| Book Value Per Share | 4.17 |
| Working Capital | 270.68M |
Cash Flow
In the last 12 months, operating cash flow was -$169.92 million and capital expenditures -$64,237, giving a free cash flow of -$168.30 million.
| Operating Cash Flow | -169.92M |
| Capital Expenditures | -64,237 |
| Depreciation & Amortization | 154,361 |
| Net Borrowing | -200,909 |
| Free Cash Flow | -168.30M |
| FCF Per Share | -$2.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharvaris does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.13% |
| Shareholder Yield | -14.13% |
| Earnings Yield | -8.29% |
| FCF Yield | -7.18% |
Analyst Forecast
The average price target for Pharvaris is $46.59, which is 38.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.59 |
| Price Target Difference | 38.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |